National Comprehensive Cancer Network

About NCCN

UPDATES: NCCN Guidelines® and NCCN Compendium®

NCCN Flash Update sent March 3, 2014

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Myeloid Growth Factors. These NCCN Guidelines® are currently available as Version 1.2014.

  • Examples of Disease Settings and Chemotherapy Regimens
    • Myelodysplastic Syndromes: Decitabine was removed from the examples of chemotherapy regimens with a high risk for febrile neutropenia (>20%). (MGF-A 1 of 4)
    • Breast Cancer: TC (docetaxel, cyclophosphamide) was added to the examples of chemotherapy regimens with an intermediate risk for febrile neutropenia (10%-20%) with a footnote stating, “Risk for febrile neutropenia has been reported variably as intermediate risk or high risk depending on the study.” (MGF-A 2 of 4)
  • Myeloid Growth Factors in Mobilization and Post Stem Cell Transplant (MGF-F 1 of 2)
    • “G-CSF” was replaced with “filgrastim.”

For the complete updated versions of the NCCN Guidelines, the NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.

To access the NCCN Biomarkers Compendium™, please visit NCCN.org/biomarkers.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.

Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps